Expression of CD68 positive macrophages in the use of different barrier materials to prevent peritoneal adhesions—an animal study

Brochhausen, Christoph; Schmitt, Volker H.; Mamilos, Andreas; Schmitt, Christine; Planck, Constanze N. E.; Rajab, Taufiek Konrad; Hierlemann, Helmut; Kirkpatrick, Charles James

doi:10.1007/s10856-016-5821-3

Cited by 29 publications

(30 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cells produce pro-inflammatory cytokines that kill pathogens and other foreign materials. These macrophages also produce diverse growth factors involved in controlling inflammation, restoring wound tissue, and healing [ 30 ]. CD68 is a glycoprotein and an indicator of wound healing macrophages.…”

Section: Resultsmentioning

confidence: 99%

Topical Wound Healing Activity of Myricetin Isolated from Tecomaria capensis v. aurea

et al. 2020

View full text Add to dashboard Cite

Wounds and burn injury are major causes of death and disability worldwide. Myricetin is a common bioactive flavonoid isolated naturally from the plant kingdom. Herein, a topical application of naturally isolated myricetin from the shoots of Tecomaria capensis v. aurea on excisional wound healing that was performed in albino rats. The wounded rats were treated every day with 10 and 20% myricetin for 14 days. During the experiment, the wound closure percentage was estimated at days 0, 7, and 14. Effects of myricetin on the inflammatory cytokines (tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and cluster of differentiation 68 (CD68) in the serum were evaluated using immunosorbent assay kits. The percentage of wound closure and contraction was delayed in wounded rats (67.35%) and was remarkably increased after treatment of wounded rats with myricetin; the treatment with 20% myricetin was the most potent (98.76%). Histological findings exhibited that 10% myricetin caused the formation of a large area of scarring at the wound enclosure and stratified squamous epithelium without the formation of papillae as in the control group. Treatment with 20% myricetin exhibited less area of scarring at the wound enclosure as well as re-epithelialization with a high density of fibroblasts and blood capillaries in the wound. Level elevations of serum pro-inflammatory cytokines, IL-1β, and TNF-α and macrophage CD68 were decreased in wounded rats treated with myricetin. Thus, it can be suggested that the enhancements in inflammatory cytokines as well as systemic reorganization after myricetin treatment may be recommended to play a crucial part in the promotion of wound healing. The findings suggest that treatment with a higher dose of myricetin was better in improving wound curing in rats. It could serve as a potent anti-inflammatory agent and can be used as an adjunctive or alternative agent in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Topical Wound Healing Activity of Myricetin Isolated from Tecomaria capensis v. aurea

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nondefect Grhl3 fetuses injected IHC: cellular inflammatory response CD68 and F4/80 are both commonly used macrophage markers to assess the inflammatory response of applied biomaterials. [37][38][39][40] The RTG injection into nondefect mouse fetuses shows a significant increase in F4/80-positive cells (mean: 55.1 cells [SE ¼ 10.9], P < 0.001) when compared with saline injected nondefect mouse fetuses (mean: 31.…”

Section: Morphology: Hande Stainingmentioning

confidence: 99%

An Injectable Reverse Thermal Gel for Minimally Invasive Coverage of Mouse Myelomeningocele

Bardill

Williams

Shabeka

et al. 2019

Journal of Surgical Research

View full text Add to dashboard Cite

Background: Myelomeningocele (MMC) results in lifelong neurologic and functional deficits. Currently, prenatal repair of MMC closes the defect, resulting in a 50% reduction in postnatal ventriculoperitoneal shunting. However, this invasive fetal surgery is associated with significant morbidities to mother and baby. We have pioneered a novel reverse thermal gel (RTG) to cover MMC defects in a minimally invasive manner. Here, we test in-vitro RTG long-term stability in amniotic fluid and in vivo application in the Grainy head-like 3 (Grhl3) mouse MMC model. Materials and methods: RTG stability in amniotic fluid (in-vitro) was monitored for 6 mo and measured using gel permeation chromatography and solutionegel transition temperature (lower critical solution temperature). E16.5 Grhl3 mouse fetuses were injected with the RTG or saline and harvested on E19.5. Tissue was assessed for RTG coverage of the gross defect and inflammatory response by immunohistochemistry for macrophages. Results: Polymer backbone molecular weight and lower critical solution temperature remain stable in amniotic fluid after 6 mo. Needle injection over the MMC of Grhl3 fetuses successfully forms a stable gel that covers the entire defect. On harvest, some animals demonstrate >50% RTG coverage. RTG injection is not associated with inflammation. Conclusions: Our results demonstrate that the RTG is a promising candidate for a minimally invasive approach to patch MMC. We are now poised to test our RTG patch in the large preclinical ovine model used to evaluate prenatal repair of MMC.

show abstract

“…Peritoneal adhesions following abdominal operations are results of normal wound healing and constitute a major problem in surgery. Research on methods to prevent post-operative adhesion formation has been an important field for surgeons 18,19 . Factors such as trauma, infections, foreign bodies, and ischemia may cause PPA 20 .…”

Section: Discussionmentioning

confidence: 99%

The Effect of Single-Dose Intraperitoneal Bevacizumab on Peritoneal Adhesion Formation

Acun¹,

Özdemir

Sunamak

et al. 2018

RIC

View full text Add to dashboard Cite

Background: Intra-abdominal adhesions and their complications following abdominal surgery are serious problems, with an incidence of 67-93%. Prevention of peritoneal adhesion formation may eliminate the need for surgical intervention, decreasing complications, morbidity, and cost. Bevacizumab is a recombinant monoclonal antibody which specifically binds vascular endothelial growth factor, an important cytokine in adhesion formation, and neutralizes its biological activity. We developed an experimental model in rats to determine the effect of bevacizumab in preventing adhesion formation and analyzed its effect both micro-and macroscopically. Methods: We used 32 Wistar rats randomly divided into two groups: Group A (control) and Group B (bevacizumab), with 16 rats each. A modified cecum abrasion model was developed; 0.9% NaCl solution was administered intraperitoneally to Group A and bevacizumab to Group B. On day 15, adhesion formation was evaluated both macro-and microscopically. Results: Both micro-and macroscopic adhesion grades in Group B were significantly lower than those of control Group A; macroscopic grades were 2.69 ± 0.95 and 0.69 ± 0.8, and microscopic grades were 2.25 ± 1.06 and 0.5 ± 0.52 for Groups A and B, respectively. Conclusions: Bevacizumab was effective in preventing intraperitoneal adhesion formation in our study; however, its inhibitory effects on embryogenesis and the hematopoietic, endocrine, and immune systems may limit its clinical use.

show abstract

Expression of CD68 positive macrophages in the use of different barrier materials to prevent peritoneal adhesions—an animal study

Cited by 29 publications

References 40 publications

Topical Wound Healing Activity of Myricetin Isolated from Tecomaria capensis v. aurea

Topical Wound Healing Activity of Myricetin Isolated from Tecomaria capensis v. aurea

An Injectable Reverse Thermal Gel for Minimally Invasive Coverage of Mouse Myelomeningocele

The Effect of Single-Dose Intraperitoneal Bevacizumab on Peritoneal Adhesion Formation

Contact Info

Product

Resources

About